Nav: Home

Living off the fat of the land

March 31, 2016

Cancer cells are defined by their ability for uncontrolled growth, one cell quickly becoming two becoming many. "It's a fascinating process," said Gary Patti, PhD, associate professor of chemistry at Washington University in St. Louis. "Imagine creating two copies of yourself every few days instead of just maintaining the one you have. In the past 15 or 20 years people have become really interested in how a cell does that."

For more than 80 years the reigning idea has been that cancer cells fuel their explosive growth by soaking up glucose from the blood, using its energy and atoms to crank out duplicate sets of cellular components.

One of the reasons so much glucose is taken up is to make the lipids, or fats, that are assembled into cell membranes, the thin veils that separate the contents of a cell from its environment.

In 1970s and '80s, scientists working with radioactively tagged glucose showed that practically all the lipids inside tumor cells were made from glucose the cells took up from the extracellular environment, a finding that seemingly corroborated the "glucose hypothesis."

The hypothesis makes sense, but like many other things that make sense, it may not be right.

While pursuing other work, the Patti lab discovered that proliferating fibroblasts make most of their lipids from glucose only if they are grown in standard cell-culture medium, which is nutrient-rich but lipid-poor.

When the scientists spiked the culture medium with lipids, raising concentrations to those typical of blood, the cells preferred to scavenge lipids from the medium rather than synthesizing them. And under these conditions, rapidly dividing cells took up no more glucose than cells that weren't dividing.

This effect was discovered in cultures of fibroblasts, which divide until they touch one another and then stop, giving scientists a chance to compare the metabolism of proliferating and quiescent cells. But intrigued by the "lipid effect," the scientists checked for it in two cancer-cell lines, the famous HeLa cells and a lung cancer cell line called H460. These cell lines responded less strongly but similarly to lipid concentrations.

The startling result, published online in the March 31, 2016, issue of Cell Chemical Biology, calls into question aspects of cancer research and treatment founded on the glucose hypothesis.

"It has only been possible to think about glucose metabolism at the systems level for the past few years," Patti said, referring to the new discipline of metabolomics. "Before that the technology to follow glucose through all the possible metabolic pathways just didn't exist."

Are glucose-uptake images accurate?

"The idea that increased glucose uptake is a metabolic hallmark of cancer cells is deeply embedded in our thinking. It's the basis for how we diagnose cancer and manage its treatment in the clinic," Patti said.

In diagnostic FDG-PET scans, patients are injected with a small amount of a glucose analog that includes a radioactive atom and are then scanned to create images of glucose uptake by various organs. Bright spots on these images indicate potential cancer.

Our study raises questions about the sensitivity of these scans, Patti said. "Perhaps cancer cells can live off fats floating in the blood rather than making them all out of glucose, particularly in the case of obese or diabetic patients whose blood lipid concentrations can be higher than normal."

Could this allow cancer cells to fly under the radar, leading to false negatives?

Should cancer drugs target glucose metabolism?

Because of the glucose hypothesis, scientists have devoted a lot of attention to developing cancer therapies that inhibit either glucose metabolism or lipid synthesis.

But if the assumption is wrong, would blocking glucose metabolism slow cell growth? Wouldn't the cells just scavenge lipids from their surroundings?

To test this possibility, the scientists tried dosing their cell lines with 2DG, a glucose molecule with a hydrogen atom substituted for a hydroxyl (OH-) group that gets stuck in the pathway that breaks down glucose. They found that if they spiked the cultures with lipids as well, 2DG was much less effective in slowing the growth of cancer cells.

This finding challenges the reasoning behind one strategy for killing cancer cells, Patti said. 2DG is now in clinical trials.

What about targeting lipid uptake?

If the work in the Patti lab suggests that cancer cells might not respond as hoped to drugs that block the glucose uptake, it also suggests blocking lipid uptake might be effective .

he scientists tested this idea by dosing their cultures with a drug called SSO that irreversibly binds to a lipid transporter in the cell membrane, inhibiting lipid uptake. When they did this, all three cells lines were slower to grow and divide.

Perhaps we should be thinking more about inhibiting lipid uptake, Patti said.

Cells in culture are artifacts

'The last point," Patti said, "and I think most people accept this, is that cell cultures are highly artificial systems that often give misleading results. Whether cell culture findings translate to animal models or patients is really questionable; it's hard to place a lot of trust in them," he said.

"In this case, the standard cell culture media that everyone uses has such low lipid concentrations that it really skews what the cells in culture are doing.

"Even though we all do the same cell culture in the same way it is dangerous to assume the results apply to the clinic," he said.

Washington University in St. Louis

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".